Celldex Therapeutics Statistics
Total Valuation
CLDX has a market cap or net worth of $1.60 billion. The enterprise value is $1.02 billion.
Important Dates
The last earnings date was Monday, November 3, 2025, after market close.
| Earnings Date | Nov 3, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CLDX has 66.41 million shares outstanding. The number of shares has increased by 18.40% in one year.
| Current Share Class | 66.41M |
| Shares Outstanding | 66.41M |
| Shares Change (YoY) | +18.40% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.28% |
| Owned by Institutions (%) | 92.26% |
| Float | 53.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 283.69 |
| Forward PS | 468.52 |
| PB Ratio | 2.51 |
| P/TBV Ratio | 2.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 175.52 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.67, with a Debt / Equity ratio of 0.00.
| Current Ratio | 19.67 |
| Quick Ratio | 19.13 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -27.17% and return on invested capital (ROIC) is -19.90%.
| Return on Equity (ROE) | -27.17% |
| Return on Assets (ROA) | -19.08% |
| Return on Invested Capital (ROIC) | -19.90% |
| Return on Capital Employed (ROCE) | -35.60% |
| Revenue Per Employee | $31,129 |
| Profits Per Employee | -$1.07M |
| Employee Count | 186 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.60% in the last 52 weeks. The beta is 1.33, so CLDX's price volatility has been higher than the market average.
| Beta (5Y) | 1.33 |
| 52-Week Price Change | -4.60% |
| 50-Day Moving Average | 25.37 |
| 200-Day Moving Average | 22.10 |
| Relative Strength Index (RSI) | 40.59 |
| Average Volume (20 Days) | 820,305 |
Short Selling Information
The latest short interest is 7.40 million, so 11.14% of the outstanding shares have been sold short.
| Short Interest | 7.40M |
| Short Previous Month | 7.08M |
| Short % of Shares Out | 11.14% |
| Short % of Float | 13.90% |
| Short Ratio (days to cover) | 6.85 |
Income Statement
In the last 12 months, CLDX had revenue of $5.79 million and -$199.61 million in losses. Loss per share was -$3.01.
| Revenue | 5.79M |
| Gross Profit | -193.22M |
| Operating Income | -234.75M |
| Pretax Income | -199.61M |
| Net Income | -199.61M |
| EBITDA | -231.41M |
| EBIT | -234.75M |
| Loss Per Share | -$3.01 |
Full Income StatementBalance Sheet
The company has $630.34 million in cash and $3.03 million in debt, giving a net cash position of $627.31 million or $9.45 per share.
| Cash & Cash Equivalents | 630.34M |
| Total Debt | 3.03M |
| Net Cash | 627.31M |
| Net Cash Per Share | $9.45 |
| Equity (Book Value) | 655.41M |
| Book Value Per Share | 9.87 |
| Working Capital | 615.44M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$186.19 million and capital expenditures -$2.29 million, giving a free cash flow of -$188.48 million.
| Operating Cash Flow | -186.19M |
| Capital Expenditures | -2.29M |
| Free Cash Flow | -188.48M |
| FCF Per Share | -$2.84 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -4,054.40% |
| Pretax Margin | -3,447.48% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CLDX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.40% |
| Shareholder Yield | -18.40% |
| Earnings Yield | -12.14% |
| FCF Yield | -11.47% |
Dividend DetailsAnalyst Forecast
The average price target for CLDX is $44.20, which is 83.33% higher than the current price. The consensus rating is "Buy".
| Price Target | $44.20 |
| Price Target Difference | 83.33% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 148.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on February 11, 2019. It was a reverse split with a ratio of 1:15.
| Last Split Date | Feb 11, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
CLDX has an Altman Z-Score of 25.5 and a Piotroski F-Score of 1.
| Altman Z-Score | 25.5 |
| Piotroski F-Score | 1 |
